Literature DB >> 35059908

Neutrophil-to-lymphocyte ratio change predicts histological response to and oncological outcome of neoadjuvant chemotherapy for esophageal squamous cell carcinoma.

Shota Hoshino1, Masashi Takeuchi1, Hirofumi Kawakubo2, Ryota Kobayashi1, Satoru Matsuda1, Tomoyuki Irino1, Kazumasa Fukuda1, Rieko Nakamura1, Yuko Kitagawa1.   

Abstract

BACKGROUND: Evaluating tumor response to neoadjuvant chemotherapy (NAC) is important to predict survival and to select the optimal strategy for patients with esophageal cancer. The aim of this study is to investigate the relation between neutrophil-to-lymphocyte ratio (NLR) change after NAC and histological response and oncological outcomes in patients with esophageal cancer.
METHODS: This study enrolled 209 patients who underwent NAC and thoracic esophagectomy for esophageal cancer as the primary treatment between 2000 and 2019 in our department. Several predictors of survival including NLR change, which was calculated as post-NAC NLR/pre-NAC NLR, were investigated. We used classification and regression tree (CART) analysis to determine the optimal cutoff values of NLR change for the prediction of histological response.
RESULTS: The best cutoff value of NLR change was 0.55 using the CART analysis. Then we divided all patients into two groups; the patients with NLR change below the cutoff were allocated to the NLR reduction group (n = 53), whereas the patients with NLR change above the cutoff were allocated to the no-NLR reduction group (n = 156). NLR change was identified as a significant predictor for histological responder (odds ratio 3.80; 95% confidence interval (CI) 1.69-8.58; p = 0.001) and recurrence-free survival (hazard ratio 0.55; 95% CI 0.33-0.89; p = 0.015) in multivariable analysis.
CONCLUSION: The present study demonstrated that NLR change is associated with both histological response to and oncological outcomes of NAC for patients with esophageal cancer. NLR change can help not only to predict survival, but also to facilitate personalized multidisciplinary treatment.
© 2021. The Author(s) under exclusive licence to The Japan Esophageal Society.

Entities:  

Keywords:  Esophageal cancer; Neoadjuvant chemotherapy; Neutrophil-to-lymphocyte ratio

Mesh:

Year:  2022        PMID: 35059908     DOI: 10.1007/s10388-021-00901-6

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  6 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  ASO Author Reflections: The Negative Impact of Postoperative Complications on Long-Term Outcomes After Esophagectomy: The Influence of Neoadjuvant Therapy and Future Perspectives.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2019-09-13       Impact factor: 5.344

3.  Usefulness of Neutrophil to Lymphocyte Ratio at Recurrence for Predicting Long-Term Outcomes in Patients with Recurrent Esophageal Squamous Cell Carcinoma.

Authors:  Shota Hoshino; Masashi Takeuchi; Hirofumi Kawakubo; Satoru Matsuda; Shuhei Mayanagi; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2021-03-10       Impact factor: 5.344

4.  Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.

Authors:  Satoru Matsuda; Hirofumi Kawakubo; Akihiko Okamura; Keita Takahashi; Tasuku Toihata; Ryo Takemura; Shuhei Mayanagi; Kenro Hirata; Tomoyuki Irino; Yasuo Hamamoto; Hiroya Takeuchi; Masayuki Watanabe; Yuko Kitagawa
Journal:  Ann Surg       Date:  2020-10-16       Impact factor: 13.787

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Predictive value of immuno-inflammatory and nutritional measures modulated by neoadjuvant chemotherapy on the response of neoadjuvant chemotherapy and long-term outcomes in patients with esophageal cancer.

Authors:  Yusuke Ishibashi; Hironori Tsujimoto; Shuichi Hiraki; Keita Kouzu; Satoshi Tsuchiya; Yujiro Itazaki; Yoshihisa Yaguchi; Hiroyuki Horiguchi; Shinsuke Nomura; Nozomi Ito; Eiji Shinto; Yoji Kishi; Hideki Ueno
Journal:  Oncol Lett       Date:  2019-11-19       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.